Related Experiment Video
Updated: Mar 15, 2026

Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility
Published on: April 13, 2017
Methionine enkephalin regulates microglia polarization and function
1Department of Neurology, Shengjing Hospital, Affiliated Hospital of China Medical University, Shenyang 110004, PR China.
Abstract:
Methionine enkephalin (MENK), an opioid peptide, is known to function as a regulator in the immune system. As microglia are considered the most important immune cells in the central nervous system (CNS), we aimed to assess the function of MENK on microglia polarization and tumoricidal responses. Initially, we chose the most optimal condition of 10-12M for 48h; however, MENK had no function on the viability and apoptosis of microglia under this treatment. However, MENK treatment markedly increased levels of M1-associated genes, such as CD86, CD40, IL-12, and TNF-α, but had no effect on M2 markers, including CD163, IL-10, and TGF-β. Moreover, microglia in the MENK-treated group showed high phagocytosis capacity, which coincided with characteristics of M1 microglia. MENK stimulation also induced up-regulation of reactive oxygen species (ROS) expression, which contributed to maintaining homeostasis. We also detected NO production by measuring the end product nitrite, and found that MENK treatment increased expression of nitrite and inducible NO synthase (iNOS), but did not influence arginase-1 (Arg1) expression. Furthermore, treatment of microglia with MENK led to a significant increase in cytotoxicity against glioblastoma cells, indicating that MENK possessed anti-tumor ability. Overall, MENK treatment could induce microglia to an M1 phenotype, modulating Th1 responses in the immune system. Additionally, microglia treated with MENK had tumoricidal activity, which provides new insight into anti-tumor immunity.
Insights
Methionine enkephalin (MENK) promotes microglia to an M1 phenotype, enhancing their tumoricidal activity against glioblastoma. This opioid peptide shows potential for modulating anti-tumor immunity in the central nervous system.
Area of Science:
- Neuroimmunology
- Cancer Immunology
Background:
- Microglia are key immune cells in the central nervous system (CNS).
- Methionine enkephalin (MENK) is an opioid peptide that regulates immune responses.
Purpose of the Study:
- To investigate the effect of MENK on microglia polarization.
- To assess MENK's impact on microglia's tumoricidal responses against glioblastoma.
Main Methods:
- Treatment of microglia with MENK (10-12M for 48h).
- Analysis of M1/M2 marker gene expression (CD86, CD40, IL-12, TNF-α, CD163, IL-10, TGF-β).
- Assessment of phagocytosis, reactive oxygen species (ROS), nitric oxide (NO) production, and cytotoxicity against glioblastoma cells.
Main Results:
- MENK induced an M1 microglia phenotype, upregulating M1 markers and phagocytosis.
- MENK increased ROS and NO production (via iNOS) without affecting M2 markers or arginase-1.
- MENK-treated microglia exhibited significant cytotoxicity against glioblastoma cells.
Conclusions:
- MENK drives microglia towards an M1 phenotype, enhancing anti-tumor immunity.
- MENK demonstrates potential as a therapeutic agent for glioblastoma by activating microglia-mediated tumoricidal activity.

